US2021128601A1PendingUtilityA1
Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: Jun 5, 2015Filed: Jan 11, 2021Published: May 6, 2021
Est. expiryJun 5, 2035(~8.8 yrs left)· nominal 20-yr term from priority
A61P 27/04A61K 31/7084A61P 27/02A61K 47/18A61K 9/08A61K 9/0048A61K 47/10A61K 47/14A61K 31/7072A61K 31/155
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
Claims
exact text as granted — not AI-modified1 . A therapeutic agent for dry eye characterized by being applied to an eye of a dry eye patient wearing soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride.
2 . The therapeutic agent according to claim 1 , which is contained in a unit-dose type container.
3 . The therapeutic agent according to claim 1 , which is contained in a multi-dose type container.
4 . The therapeutic agent according to claim 3 , which comprises a preservative other than benzalkonium chloride.
5 . The therapeutic agent according to claim 4 , wherein the preservative other than benzalkonium chloride is at least one selected from the group consisting of chlorhexidines, borates, chlorites, parabenes, sorbates, chlorobutanol and benzethonium chloride.
6 . The therapeutic agent according to claim 4 , wherein the preservative other than benzalkonium chloride is chlorhexidines.
7 . The therapeutic agent according to claim 1 , wherein a concentration of the diquafosol or a salt thereof is 0.5 to 5% (w/v).
8 . The therapeutic agent according to claim 1 , wherein a concentration of the diquafosol or a salt thereof is 3% (w/v).
9 . The therapeutic agent according to claim 1 , wherein the dry eye is caused by wearing contact lenses.
10 . An ophthalmic solution for improving tear film stability, characterized by being applied to an eye wearing a soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride.
11 . An ophthalmic solution for treating eye dryness or eye discomfort caused by wearing the soft contact lens, characterized by being applied to an eye wearing a soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride.Join the waitlist — get patent alerts
Track US2021128601A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.